The Reading Room with Diagnostic Imaging

In a recent podcast episode, Jack Andrews, MD, discussed the role of PSMA PET in facilitating more targeted, metastasis-directed therapy for prostate cancer and recent phase 4 research comparing PSMA PET agents in men with low PSA values.

In a new podcast episode, Thomas Hope, MD, shares his insights on glioma imaging and the potential impact of the recently FDA-approved PET agent floretyrosine (18F-FET),

In a new podcast episode, Sharmila Dorbala, MD, MPH, shares her insights on recently published phase 3 research examining the use of the PET/CT radiotracer 124I-evuzamitide for bolstering detection of cardiac amyloidosis.

In a new podcast episode, Manisha Bahl, MD, MPH, FSBI, offers pertinent insights into a recent study assessing whether AI models for breast cancer detection and short-term risk prediction can be used interchangeably.

In a new podcast episode, Manisha Bahl, MD, MPH, FSBI, discusses recently published guidelines on proliferative breast lesions with atypia and lobular carcinoma in situ (LCIS).

In the second of a two-part podcast episode, Kalpana Kanal, PhD, and Mahadevappa Mahesh, PhD, discussed the possible impact of new research showing significant declines in CT radiation dosing over the past decade, future research directions and the potential for indication-based diagnostic reference levels (DRLs) in the future.

In the first of a two-part podcast episode, Kalpana Kanal, PhD, and Mahadevappa Mahesh, PhD, reviewed key findings from a study examining CT radiation dosing over the past decade and shared insights from their experience for ensuring optimal radiation dosing for CT scans.

In a recent podcast episode, Joseph Cavallo, MD, MBA, offered his perspective on AI integration, potential efficiency gains, navigating post-deployment monitoring and how to incorporate AI literacy into radiology resident training.

In a new podcast episode, Amir Iravani, MD, FRACP, discusses emerging dosimetry data from the COMPETE trial for 177Lu-edotreotide and how it may help facilitate more personalized treatment for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).